Press release
May 23, 2023  ·  Regulatory information

Cantargia publishes interim report for the first quarter of 2023

Cantargia AB’s (”Cantargia”) interim report for the first quarter of 2023 is now available on the company’s web page

Significant events in the first quarter

  • Promising early safety and efficacy were reported for nadunolimab with chemotherapy in the first triple-negative breast cancer (TNBC) patients recruited to the dose escalation stage in the clinical phase Ib/II trial TRIFOUR. Soon thereafter, the first patient was treated in the subsequent randomized phase II stage.
  • The GLP toxicity study for CAN10 was successfully completed.
  • Patrik Renblad was recruited as new Chief Financial Officer (CFO).

Significant events after the end of the period

  • New promising efficacy data for combination therapy with nadunolimab in pancreatic cancer (PDAC) patients were presented at the AACR 2023 conference. These data showed that a subgroup of patients with high levels of IL1RAP benefit most from treatment with nadunolimab and chemotherapy. Anti-metastatic effects of nadunolimab in cancer models were also presented.
  • Plans for a new randomized clinical phase IIb trial were announced. This trial will evaluate nadunolimab in combination with gemcitabine/nab-paclitaxel in additional PDAC patients.
  • Patient enrollment to the CANFOUR trial was completed. Favorable safety was reported for nadunolimab with carboplatin/pemetrexed in the ten treated non-squamous non-small cell lung cancer (NSCLC) patients. Biomarkers will now be evaluated in all treated NSCLC patients.
  • An application to start the first clinical trial for CAN10 was submitted to regulatory authorities.

Financial information

First Quarter 2023
Net sales: SEK 0 M (0)
Operating loss: SEK -77.6 M (-121.6)
Loss after tax: SEK -75.9 M (-117.5)
Loss per share: before and after dilution, SEK -0.45 (-1.17)
Equity/assets ratio: 77 (82) per cent
Cash and cash equivalents: SEK 155.4 M (205.7)
Short-term investments: SEK 197.4 M (237.1)

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on May 23, at 10:00 a.m. CEST, where the company management will present Cantargia and comment on the quarterly report for the first quarter of 2023, followed by a Q&A-session.

If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast:

If you wish to participate via teleconference, please register via the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

The webcast will also be available on demand on Cantargia’s corporate website: